These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 15958055)
1. Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated-type breast carcinomas with 'stem-cell-like' features. Tsuda H; Tani Y; Weisenberger J; Kitada S; Hasegawa T; Murata T; Tamai S; Hirohashi S; Matsubara O; Natori T Cancer Sci; 2005 Jun; 96(6):333-9. PubMed ID: 15958055 [TBL] [Abstract][Full Text] [Related]
2. Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. Tsuda H; Morita D; Kimura M; Shinto E; Ohtsuka Y; Matsubara O; Inazawa J; Tamaki K; Mochizuki H; Tamai S; Hiraide H Cancer Sci; 2005 Jan; 96(1):48-53. PubMed ID: 15649255 [TBL] [Abstract][Full Text] [Related]
3. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Reis-Filho JS; Milanezi F; Carvalho S; Simpson PT; Steele D; Savage K; Lambros MB; Pereira EM; Nesland JM; Lakhani SR; Schmitt FC Breast Cancer Res; 2005; 7(6):R1028-35. PubMed ID: 16280056 [TBL] [Abstract][Full Text] [Related]
4. Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. Sawada M; Tsuda H; Kimura M; Okamoto S; Kita T; Kasamatsu T; Yamada T; Kikuchi Y; Honjo H; Matsubara O Cancer Sci; 2003 Nov; 94(11):986-91. PubMed ID: 14611676 [TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Gilbert JA; Goetz MP; Reynolds CA; Ingle JN; Giordano KF; Suman VJ; Blair HE; Jenkins RB; Lingle WL; Reinholz MM; Adjei AA; Ames MM Mol Cancer Ther; 2008 Apr; 7(4):944-51. PubMed ID: 18413808 [TBL] [Abstract][Full Text] [Related]
6. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793 [TBL] [Abstract][Full Text] [Related]
7. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Dabbs DJ; Chivukula M; Carter G; Bhargava R Mod Pathol; 2006 Nov; 19(11):1506-11. PubMed ID: 16941011 [TBL] [Abstract][Full Text] [Related]
8. A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas. Dias-Santagata D; Lam Q; Bergethon K; Baker GM; Iafrate AJ; Rakheja D; Hoang MP Mod Pathol; 2011 Jul; 24(7):974-82. PubMed ID: 21423156 [TBL] [Abstract][Full Text] [Related]
9. Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach. Murakawa T; Tsuda H; Tanimoto T; Tanabe T; Kitahara S; Matsubara O Pathol Int; 2005 Dec; 55(12):757-65. PubMed ID: 16287490 [TBL] [Abstract][Full Text] [Related]
10. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Bryan BB; Schnitt SJ; Collins LC Mod Pathol; 2006 May; 19(5):617-21. PubMed ID: 16528377 [TBL] [Abstract][Full Text] [Related]
11. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes. Di Palma S; Simpson RH; Marchiò C; Skálová A; Ungari M; Sandison A; Whitaker S; Parry S; Reis-Filho JS Histopathology; 2012 Oct; 61(4):629-43. PubMed ID: 22882517 [TBL] [Abstract][Full Text] [Related]
12. Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation. Shien T; Tashiro T; Omatsu M; Masuda T; Furuta K; Sato N; Akashi-Tanaka S; Uehara M; Iwamoto E; Kinoshita T; Fukutomi T; Tsuda H; Hasegawa T J Clin Pathol; 2005 Dec; 58(12):1299-304. PubMed ID: 16311351 [TBL] [Abstract][Full Text] [Related]
13. Expression of c-kit in common benign and malignant breast lesions. Kondi-Pafiti A; Arkadopoulos N; Gennatas C; Michalaki V; Frangou-Plegmenou M; Chatzipantelis P Tumori; 2010; 96(6):978-84. PubMed ID: 21388062 [TBL] [Abstract][Full Text] [Related]
14. P53, c-erbB-2 expression and steroid hormone receptors in breast carcinoma: correlations with histopathological parameters. Kilinç N; Yaldiz M Eur J Gynaecol Oncol; 2004; 25(5):606-10. PubMed ID: 15493177 [TBL] [Abstract][Full Text] [Related]
16. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662 [TBL] [Abstract][Full Text] [Related]
17. Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables. Mohammadizadeh F; Naimi A; Rajabi P; Ghasemibasir H; Eftekhari A Indian J Med Sci; 2009 Apr; 63(4):152-62. PubMed ID: 19414985 [TBL] [Abstract][Full Text] [Related]
18. Expression of c-erbB3 protein in primary breast carcinomas. Naidu R; Yadav M; Nair S; Kutty MK Br J Cancer; 1998 Nov; 78(10):1385-90. PubMed ID: 9823984 [TBL] [Abstract][Full Text] [Related]
19. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin. Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031 [TBL] [Abstract][Full Text] [Related]
20. Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. Wang X; Jones TD; Zhang S; Eble JN; Bostwick DG; Qian J; Lopez-Beltran A; Montironi R; Harris JJ; Cheng L Mod Pathol; 2007 Feb; 20(2):175-82. PubMed ID: 17192792 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]